Literature DB >> 15619154

Cholesterol, transferrin saturation, and the development of dementia and Alzheimer's disease: results from an 18-year population-based cohort.

Arch G Mainous1, Stephanie L Eschenbach, Brian J Wells, Charles J Everett, James M Gill.   

Abstract

BACKGROUND AND OBJECTIVES: Oxidative stress plays a role in Alzheimer's disease (AD), and iron and cholesterol together have been linked to oxidative stress. This study examined the relationship between transferrin saturation (TS) and cholesterol to see if both are necessary to increase the risk for the subsequent development of AD.
METHODS: We analyzed data from US adults (ages 40-74 years at baseline) followed from baseline in 1971-1974 to 1992 (n=6,558) in the cohort study, the National Health and Nutrition Examination Survey I Epidemiologic Followup Study (NHEFS).
RESULTS: The unadjusted relative risk of developing AD when both TS and cholesterol were at the 75th percentile was 3.19 (95% CI, 1.31-7.75). In adjusted models when only one marker was elevated, there was no significant increased risk for AD. The risk of AD increased as both markers increased. Even at the 85th percentile, individuals had no significant risk of AD when only having elevated cholesterol (>280 mg/dl) but not elevated TS (39.6%). Findings were similar for individuals with elevated TS but not elevated cholesterol.
CONCLUSIONS: In this population-based cohort, the risk of developing AD when one has both elevated cholesterol and elevated TS is much larger than the risk associated with elevation of either of these factors alone.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15619154

Source DB:  PubMed          Journal:  Fam Med        ISSN: 0742-3225            Impact factor:   1.756


  17 in total

1.  Deferiprone reduces amyloid-β and tau phosphorylation levels but not reactive oxygen species generation in hippocampus of rabbits fed a cholesterol-enriched diet.

Authors:  Jaya R P Prasanthi; Matthew Schrag; Bhanu Dasari; Gurdeep Marwarha; April Dickson; Wolff M Kirsch; Othman Ghribi
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

Review 2.  Dyslipidemia and dementia: current epidemiology, genetic evidence, and mechanisms behind the associations.

Authors:  Christiane Reitz
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

3.  Neurovascular changes measured by time-of-flight MR angiography in cholesterol-fed rabbits with cortical amyloid beta-peptide accumulation.

Authors:  Susan K Lemieux; Carrie A Smith-Bell; Jered R Wells; Nnadozie M Ezerioha; Jeffrey S Carpenter; D Larry Sparks; Bernard G Schreurs
Journal:  J Magn Reson Imaging       Date:  2010-08       Impact factor: 4.813

Review 4.  Alzheimer disease--no target for statin treatment. A mini review.

Authors:  Siegfried Hoyer; Peter Riederer
Journal:  Neurochem Res       Date:  2006-10-25       Impact factor: 3.996

5.  Elevated transferrin saturation, health-related quality of life and telomere length.

Authors:  Arch G Mainous; Robert U Wright; Mary M Hulihan; Waleed O Twal; Christine E McLaren; Vanessa A Diaz; Gordon D McLaren; W Scott Argraves; Althea M Grant
Journal:  Biometals       Date:  2013-12-15       Impact factor: 2.949

Review 6.  Blood Pressure and Statin Effects on Cognition: a Review.

Authors:  Mia Yang; Jeff Williamson
Journal:  Curr Hypertens Rep       Date:  2019-07-26       Impact factor: 5.369

Review 7.  Promoting successful cognitive aging: a comprehensive review.

Authors:  Kirk R Daffner
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

Review 8.  Dyslipidemia and the risk of Alzheimer's disease.

Authors:  Christiane Reitz
Journal:  Curr Atheroscler Rep       Date:  2013-03       Impact factor: 5.113

9.  On cholesterol levels and statins in cognitive decline and Alzheimer disease: progress and setbacks.

Authors:  Marwan N Sabbagh; Kabir Thind; David Larry Sparks
Journal:  Alzheimer Dis Assoc Disord       Date:  2009 Oct-Dec       Impact factor: 2.703

Review 10.  Cardiovascular risk factors and incident Alzheimer disease: a systematic review of the literature.

Authors:  Christianna Purnell; Sujuan Gao; Christopher M Callahan; Hugh C Hendrie
Journal:  Alzheimer Dis Assoc Disord       Date:  2009 Jan-Mar       Impact factor: 2.703

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.